© Copyright - Newspaper WordPress Theme by TagDiv
Ursodeoxycholic Acid
Also known as / Synonyms: Ursodiol, UDCA, Ursodeoxycholic Acid
Naturally occurring hydrophilic bile acid treating cholestatic liver disease and dissolving gallstones.
Clinical Snapshot & Specifications
Approved Indications & Medical Uses
- Treatment of primary biliary cholangitis (PBC) to delay disease progression.
- Dissolution of radiolucent, non-calcified gallstones (< 20 mm) in patients with a functioning gallbladder.
- Intrahepatic cholestasis of pregnancy (ICP) for relief of pruritus and transaminase normalization.
- Nonalcoholic steatohepatitis (NASH) and cystic fibrosis-related hepatobiliary disease (adjunctive).
Contraindications (Do Not Use If…)
- Calcified or radiopaque gallstones, pigment stones, or non-functioning gallbladder.
- Acute cholecystitis, acute cholangitis, or complete biliary tract obstruction.
- Severe hepatic failure or active peptic ulcer disease.
- Known hypersensitivity to ursodeoxycholic acid or bile acids.
Important Clinical Precautions & Warnings
- Liver function monitoring: monitor AST, ALT, alkaline phosphatase, and bilirubin monthly for the first 3 months, then every 6 months.
- Gallstone dissolution criteria: requires serial ultrasound monitoring every 6 months; therapy may take 6 to 24 months.
- Strict compliance: gallstones may recur after cessation of therapy.
- Take with meals or milk to enhance intestinal emulsification and absorption.
Special Populations (Paediatric & Geriatric Care)
Pediatric: Used in cystic fibrosis-related liver disease (ages >= 6 years); dosage 20 mg/kg/day. Elderly: No specific dosage restrictions; monitor liver biochemistry.
Side Effects & Adverse Reactions
Common Side Effects (Usually Mild)
Diarrhea or loose stools, nausea, abdominal discomfort, indigestion, rash, and transient hair thinning.
Serious Side Effects — Seek Urgent Medical Care
Biliary colic from mobilizing gallstones, severe hepatotoxicity, calcification of gallstones, and hypersensitivity reactions.
Action: Discontinue medication and seek immediate medical attention or call emergency services if any serious symptom occurs.
Drug, Food & Substance Interactions
- Bile acid sequestrants (cholestyramine, colestipol): bind UDCA in the gut and eliminate its efficacy; space by >= 4 hours.
- Aluminum hydroxide antacids: decrease UDCA absorption.
- Estrogens and oral contraceptives: increase biliary cholesterol secretion, countering gallstone dissolution.
- Ciprofloxacin and dapsone: potential altered bioavailability.
Pregnancy & Lactation Clinical Safety
Pregnancy Safety:
Use with caution — see notesWidely utilized and guideline-endorsed in the 2nd and 3rd trimesters for intrahepatic cholestasis of pregnancy (ICP); consult obstetrician.
Lactation & Breastfeeding:
Use with caution — see notesExcretion in human milk is negligible; no adverse events have been noted in nursing infants.
Storage, Administration & Overdose Protocol
🌡️ Recommended Storage:
Store below 30°C in a dry place. Protect from heat and direct sunlight.
⏱️ Missed Dose Protocol:
Take in divided doses with food, or single dose at bedtime. If forgotten, take with the next meal. Do not take double tablets.
Accidental overdose is likely to result primarily in diarrhea. Provide oral rehydration and electrolyte replacement.
Clinical Sources & Regulatory References
Statutory drug monograph citations and regulatory databases consulted for clinical synthesis.
Every clinical monograph on 4mg.in is continuously cross-referenced against official pharmacopoeias, national formulary compendia, and statutory regulatory filings to guarantee therapeutic precision:
Central Drugs Standard Control Organisation, Ministry of Health and Family Welfare. Evaluated for approved indications, Schedule H/H1 status, and National List of Essential Medicines (NLEM).
CDSCO Official Portal →U.S. Food and Drug Administration Approved Prescribing Information, Package Inserts, and Pharmacovigilance Black Box Warnings repository via NLM DailyMed.
Search FDA Labels on DailyMed →WHO Model List of Essential Medicines (23rd List) and WHO Collaborating Centre for Drug Statistics Methodology (Anatomical Therapeutic Chemical - ATC / DDD Index).
WHO Essential Medicines Registry →National Center for Biotechnology Information (NCBI). Peer-reviewed clinical trials, bioavailability investigations, and Cochrane systematic reviews.
Query PubMed Studies for Ursodeoxycholic Acid →
4mg Clinical Pharmacology Team. Ursodeoxycholic Acid Monograph: Uses, Dosage, Contraindications & Interactions. Medically reviewed by licensed clinical editors. 4mg.in, 2026. Available at: https://4mg.in/medicines/ursodeoxycholic-acid/
